BullFrog AI and Eleison Pharma Collaborate to Optimize Phase 3 Trial

BullFrog AI Holdings, Inc., a company specializing in AI-driven drug development, has announced a new collaboration with Eleison Pharmaceuticals Inc. Eleison, a Phase 3 oncology company, aims to enhance its clinical trials for rare cancer treatments by leveraging BullFrog's innovative AI solutions. The partnership focuses on utilizing BullFrog's BullFrog Data Networks™ to improve the effectiveness of clinical trials and provide deeper insights into patient outcomes.

Vin Singh, CEO of BullFrog AI, emphasized the transformative potential of AI in clinical trials, highlighting its ability to mitigate risks in drug development and enhance patient care. Through this collaboration, BullFrog aims to apply its proprietary bfLEAP® platform to Eleison's ongoing studies, particularly focusing on glufosfamide, a promising treatment for pancreatic cancer.

Glufosfamide, currently in Phase 3 trials, represents a novel approach to cancer treatment as a third-generation alkylating agent. Designed for better targeting and uptake by tumors, it minimizes systemic toxicity and side effects. Despite pancreatic cancer being relatively rare, it remains a leading cause of cancer-related deaths in the United States, with dismal five-year survival rates under 5%. Eleison is optimistic about the potential impact of this treatment and anticipates completing the current trial by 2027.

The collaboration will see BullFrog AI deploying its bfLEAP® technology to analyze data from Eleison’s past and present clinical trials. This analysis aims to refine patient selection processes, identify predictive biomarkers, and boost the efficiency of future trials. Additionally, BullFrog's insights will support Eleison’s upcoming trials for other oncology treatments, including inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). These developments are expected to streamline Eleison’s drug development processes and enhance decision-making across its oncology portfolio.

Eleison's CEO, Edwin Thomas, expressed excitement about the partnership, noting the benefits of integrating AI analytics to gain a better understanding of patient responses and safety profiles. This strategic move is anticipated to benefit not only the current glufosfamide program but also to guide the development of Eleison’s broader range of oncology treatments.

BullFrog AI is devoted to advancing drug discovery through AI and machine learning, aiming to reduce failure rates in clinical trials and streamline the development of new therapeutics. The company collaborates with research institutions to harness causal AI and its bfLEAP™ platform to analyze complex biological data efficiently.

Eleison Pharmaceuticals is committed to acquiring and developing drugs with substantial safety and efficacy data. Founded in 2009, the company focuses on bringing new cancer treatments to market, working with international partners in countries such as China, South Korea, and Israel. Besides its glufosfamide project, Eleison is progressing with late-stage clinical trials for treatments targeting small cell lung cancer, pediatric osteosarcoma, and brain cancers.

This partnership between BullFrog AI and Eleison Pharmaceuticals marks a significant advancement in the application of AI within the pharmaceutical industry, demonstrating the potential of technology to accelerate the development of life-saving cancer therapies and improve outcomes for patients worldwide.